Vice President – Mergers and Acquisitions
Iterative Health
Vice President – Mergers and Acquisitions
Iterative Health
AI-powered polyp detection for colorectal cancer
Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes.
We built a leading performance-driven network of 100+ sites across the US, Europe, India, and Australia, conducting research directly in the communities where care is delivered across gastrointestinal, hepatology, obesity, and cardiology. By combining deep clinical trial expertise with cutting-edge AI, we connect sponsors' scientific ambitions with high-performing research teams that expedite and expand access to novel therapeutics for patients in need. Today, Iterative Health is headquartered in Cambridge, Massachusetts, and New York City with 250+ employees world-wide.
The Vice President, M&A at Iterative Health will lead the evaluation, structuring, negotiation, and execution of strategic acquisitions and other inorganic growth opportunities. Partnering closely with the Chief Development Officer, executive leadership, and cross-functional teams, this leader will own the end-to-end transaction lifecycle, from market mapping and partial target sourcing through due diligence, closing, and post-acquisition integration. This individual will also help establish a disciplined, scalable M&A function that supports the company's long-term strategic and financial objectives, including opportunities to expand our clinical research site network through acquisitions and de novo development.
Where You’ll Drive Impact
How We Work
Benefits That Support You
We believe great teams do their best work when they feel supported — professionally and personally.
At Iterative Health, we’re actively working towards creating an environment that is representative of the diversity of patients our technology serves. We are focused on building an equitable and inclusive culture, and by extension, hiring process. If you require any accommodations to make the application process or interviewing experience more accessible to you, please contact [email protected].
AI-powered polyp detection for colorectal cancer
Iterative Health develops and deploys AI-powered tools for gastrointestinal (GI) care. Its main product is SKOUT®, an FDA-cleared device that helps doctors find adenomas (polyps) during GI procedures, supporting clinical judgment rather than replacing it. The company also offers AI-enabled documentation and data standardization technologies to improve the quality of patient care and to streamline clinical trials, enabling consistent reporting across institutions. By combining AI image analysis, data-driven insights, and streamlined research workflows, Iterative Health aims to improve colorectal cancer prevention and diagnosis and to extend high-quality GI care to underserved populations around the world.
Explore more opportunities at Iterative Health